Cyclo Therapeutics Inc. (CYTH)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Cyclo Therapeutics, Inc. (CYTH) Reports Q3 Loss, Lags Revenue Estimates
Cyclo Therapeutics, Inc. (CYTH) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.29 per share a year ago.
Cyclo Therapeutics, Inc. (CYTH) Reports Q2 Loss, Misses Revenue Estimates
Cyclo Therapeutics, Inc. (CYTH) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.33 per share a year ago.
Cyclo Therapeutics Inc. (CYTH) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Cyclo Therapeutics Inc. ever had a stock split?
Cyclo Therapeutics Inc. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | N. Scott Fine CEO | NASDAQ (CM) Exchange | 23254X201 CUSIP |
| US Country | 8 Employees | - Last Dividend | 9 Dec 2020 Last Split | 23 Feb 2011 IPO Date |
Overview
Cyclo Therapeutics, Inc. is a clinical stage biotechnology company focused on the research, development, and commercialization of cyclodextrin-based products to target and treat neurodegenerative diseases. Originally operating under the name CTD Holdings, Inc., the company underwent a rebranding to Cyclo Therapeutics, Inc. in September 2019, marking a significant milestone in its corporate evolution. Cyclo Therapeutics was founded in 1990 and has its headquarters located in Gainesville, Florida. The company is spearheading innovative therapeutic approaches, primarily concentrating on addressing the urgent needs of patients affected by Niemann-Pick Type C disease and Alzheimer's disease, among other conditions.
Products and Services
- Trappsol Cyclo (hydroxypropyl beta cyclodextrin)
This flagship drug candidate epitomizes Cyclo Therapeutics’ commitment to spearheading the fight against neurodegenerative diseases. Trappsol Cyclo has earned the designation of an orphan drug and is currently undergoing rigorous evaluation through Phase III clinical trials targeted at Niemann-Pick Type C disease, a genetic disorder that significantly impacts the metabolism of cholesterol and other lipids within the body’s cells, leading to a plethora of health issues. Concurrently, this drug is also in Phase IIb clinical trials aiming to assess its potential and efficacy in the treatment of Alzheimer's disease, a condition that is synonymous with cognitive decline and is the most common cause of dementia among older adults.
- Cyclodextrins and Related Products
In addition to its primary focus on drug development, Cyclo Therapeutics engages in the sale of cyclodextrins and associated products. These offerings cater to a wide array of industries, including pharmaceutical, nutritional, and others, demonstrating the versatility and utility of cyclodextrins beyond their application in drug formulations. The utilization of these compounds spans a broad spectrum, from diagnostics to specialty drugs, highlighting their importance in various applications across the healthcare and related sectors.
